Unraveling the intricacies of small cell lung cancer: FAK splicing variants as a new feature and therapeutic vulnerability of small cell lung cancer

Small cell lung cancer (SCLC) remains one of the most aggressive and lethal malignancies, with a dismal 5-year survival rate of less than 10%, and the high metastatic potential and rapid progression of SCLC pose significant clinical challenges [1]. Despite its strong association with tobacco carcinogens, the molecular mechanisms driving SCLC pathogenesis and its resistance to therapy are not fully understood. The study by Wang et al. [2], titled “Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers,” provides a comprehensive atlas of SCLC, uncovering the complex heterogeneity, high-frequency splicing variants, and therapeutic potential of SCLC, shedding light on its pathogenesis, immune microenvironment, and actionable vulnerabilities (Fig. 1). Among this multiomics investigation, the integration of spatial proteomics with single-cell transcriptomics overcomes fundamental limitations of bulk sequencing by preserving the architectural context of the tumor microenvironment. This multi-modal approach uniquely captures spatial relationships and cellular neighborhoods, and the spatial dimension is crucial for understanding the geographical rules of immune evasion and designing effective immunotherapies. Here, we also discuss these findings, using the discovery of focal adhesion kinase (FAK) splicing variants as a central, paradigmatic example to illustrate how mRNA splicing alternatives represent a new layer of vulnerability in SCLC.

1 Heterogeneous subpopulations and stem-like cells in SCLC

The molecular features of SCLC are primarily characterized by loss-of-function mutations in tumor suppressor genes such as TP53 and RB1 [3], while high-frequency gain-of-function mutations in oncogenes remain rare. Additionally, the tumor microenvironment (TME) of SCLC exhibits strong immunosuppressive properties, limiting the efficacy of immunotherapy. One of the most striking contributions of this study is the comprehensive characterization of intratumoral heterogeneity (ITH) in SCLC using single-cell RNA sequencing (scRNA-seq) of 432 959 cells, including 190 313 cancer cells from 39 patients. The authors identified two dominant cancer cell clusters: ASCL1⁺/MKI67⁺ (21.44%) and ASCL1⁺/CRIP2⁺ (52.94%). The ASCL1⁺/CRIP2⁺ cluster persisted after initial therapy, suggesting its role in therapeutic resistance and relapse, which aligns with prior observations of SCLC’s plasticity and adaptability under treatment pressure [4].

These findings underscore the dynamic nature of SCLC and the need for therapies targeting multiple subpopulations to prevent recurrence. Combination therapies targeting both proliferative (MKI67⁺) and resistant (CRIP2⁺) subpopulations may improve outcomes. Additionally, the identification of a stem-like cell (SLC) population expressing SOX1, SOX2, and PROM1 across subtypes highlights a potential reservoir for tumor recurrence. The enrichment of MYC, WNT-β-catenin pathways, p53 suppression, and cell cycle checkpoint pathways in SLCs further underscores their role in maintaining tumorigenic potential, corroborating earlier studies on cancer stem cells in SCLC [5]. The presence of SLCs across SCLC subtypes and their association with poor outcomes highlight their potential as drivers of tumor initiation and progression. These insights pave the way for investigating stemness-targeting therapies to curb SCLC aggressiveness, and targeting SLCs via MYC or WNT inhibitors to mitigate relapse. Moreover, the understanding of SLC dynamics and their functional interactions with other cell types remains further exploration, and all these findings propose this as a key area for future investigation.

2 Immunosuppressive TME and MHC modulation as therapeutic opportunities

The immunosuppressive TME of SCLC is a major barrier to immunotherapy efficacy. Wang et al. confirmed this by demonstrating low levels of major histocompatibility complex (MHC) class I and II molecules in most cancer cells, which are critical for antigen presentation and T cell activation. However, they also uncovered heterogeneity in MHC expression, with six clusters showing low MHC-I and five exhibiting high MHC-I. Spatial proteomics further validated that cancer cells at the tumor border expressed higher MHC-I levels and were surrounded by immune cells, whereas those at the center were MHC-I-low and immune-excluded. This heterogeneity may explain the limited success of immune checkpoint inhibitors in SCLC and emphasizes the need for strategies to enhance MHC expression [6]. Notably, MHC-I expression was inversely correlated with MKI67, suggesting that proliferative cells evade immune detection. This finding aligns with prior observations in SCLC and other cancers, where immune evasion is linked to aggressive phenotypes [7,8].

Tertiary lymphoid structures (TLSs), associated with better outcomes, were more prevalent in early-stage tumors, offering a potential biomarker for immunotherapy response [9,10]. The overall immune infiltration in SCLC was not significantly different from NSCLC, challenging the notion of SCLC as an immunologically “cold” tumor [11]. Neoadjuvant therapy increased MHC-I/II expression, particularly in responders, hinting at strategies to enhance immunogenicity via upregulating MHC-I (e.g., epigenetic modulators and interferon-γ) in SCLC. In this study, the integration of spatial proteomics with single-cell transcriptomics is particularly powerful, as it moves beyond the dissociated view of cell states provided by scRNA-seq alone. It allows for the direct observation of cellular subtypes, molecular function, and spatial architecture that are lost in bulk sequencing data. While modulating MHC-I expression (e.g., using demethylating agents or HDAC inhibitors) to overcome the “immune-cold” nature of SCLC represents a compelling therapeutic concept, the mechanistic basis for its heterogeneity remains largely unknown. Key questions regarding the roles of epigenetic, transcriptional, and post-translational regulation are unanswered. Consequently, this promising avenue remains an unexplored territory in both preclinical and clinical settings, highlighting a critical gap that must be addressed to expand the efficacy of immunotherapy.

3 FAK splicing variants: high-frequency targetable alterations in SCLC

A landmark discovery of this study is the identification of FAK splicing variants as high-frequency gain-of-function alterations in 77.3% of SCLC cases, representing a paradigm shift in understanding SCLC oncogenesis. These variants (FAK6, FAK7, and FAK6/7), characterized by insertions of 18 bp (Box 6) and 21 bp (Box 7) near the autophosphorylation site Y397, result in constitutive kinase activation and hyperstimulation of mTOR/AKT pathways. Crucially, they were associated with poor prognosis and sensitivity to FAK inhibitors (e.g., PF562271) in patient-derived organoids (PDOs) and xenograft (PDX) models. Clinical trials stratifying SCLC patients by FAK variant status could validate their utility as biomarkers for FAK inhibitor response. The high frequency and oncogenic activity of FAK variants make them prime candidates for targeted therapy, aligning with prior studies demonstrating FAK’s role in cancer stemness and immune evasion [12].

These findings gain significance when contextualized among established oncogenic splicing alterations in solid tumors. Similar to MET exon 14 skipping in NSCLC [13] which leads to enhanced oncogenic signaling and sensitivity to MET inhibitors, and AR-V7 in prostate cancer [14] which drives therapy resistance, FAK splicing variants represent high-frequency, gain-of-function events and create direct therapeutic vulnerabilities in SCLC. These results underscore that dysregulated splicing is a broader hallmark of cancer, and position the discovery of FAK variants in SCLC as a part of this important paradigm.

However, the clinical translation of this therapeutic strategy hinges on overcoming several key challenges: developing variant-specific inhibitors to minimize off-target toxicity, delineating reliable biomarkers for patient stratification, and preempting resistance arising from compensatory pathway activation. Moreover, the regulatory mechanisms controlling FAK splicing remain completely unknown, presenting both a limitation and an opportunity for future research.

4 Integrative genomic and environmental analysis of SCLC mutational signature

Whole-exome sequencing of 111 SCLC tumors reaffirmed the prevalence of TP53 (70.3%) and RB1 (47.7%) mutations, consistent with prior studies [15]. However, the study also identified 11 additional high-frequency mutations (e.g., ADAMTS12, NOTCH1, and APC), expanding the genetic repertoire of SCLC. Intriguingly, mutational signature analysis linked SCLC to tobacco carcinogens (e.g., benzo[a]pyrene and NNK) and environmental pollutants (e.g., 1,3-butadiene and vinyl chloride), with smokers showing higher mutation burdens. Surprisingly, nonsmokers exhibited similar signatures, implicating secondhand smoke or air pollution in SCLC etiology [16]. The presence of these signatures in nonsmokers highlights the significant role of secondhand smoke and air pollution exposure, links specific carcinogens to SCLC pathogenesis, and emphasizes the need for public health interventions beyond primary smoking prevention. The study also identified 11 recurrently mutated genes beyond TP53 and RB1, including NOTCH1 and APC, expanding the landscape of potential therapeutic targets and underscores the molecular complexity of SCLC [3]. These data underscore the role of exogenous carcinogens in SCLC initiation and provide a framework for studying prevention strategies.

5 Limitations and future directions

Wang et al. deliver a seminal resource for the SCLC community, unraveling its cellular heterogeneity, immune evasion mechanisms, and actionable targets. The discovery of FAK splicing variants as a high-frequency oncogenic alteration opens new therapeutic avenues, while the nuanced portrayal of the TME sets the stage for rational immunotherapy combinations. This work not only advances SCLC biology but also exemplifies the power of multiomics approaches in deciphering recalcitrant cancers.

For all that, however, several limitations must be acknowledged. The predominantly Chinese cohort may not fully represent the genetic diversity of global SCLC populations. The reliance on existing FAK inhibitors rather than variant-specific compounds limits the assessment of truly targeted therapy. Most importantly, the lack of mechanistic insight into key discoveries represents significant knowledge gaps. A key unanswered question is the precise mechanistic regulation of these oncogenic FAK splicing variants. The upstream splicing factors (e.g., SR proteins and hnRNPs) and cis-regulatory elements that drive the specific inclusion or exclusion of exons in FAK pre-mRNA remain to be elucidated. Furthermore, the functional interplay between the identified SLCs and other cellular subsets within the tumor ecosystem is not fully resolved. The precise signaling pathways and niche factors that maintain SLC plasticity and govern their transition to other cell states require further investigation. Similarly, the molecular basis underlying the heterogeneous expression of MHC-I in SCLC subtypes is not completely defined. The upstream epigenetic or transcriptional regulators responsible for this suppression are still largely unknown.

Future research should focus on several key priorities. These include developing more diverse patient cohorts, investigating the mechanistic basis, and functional validation of SLC. It is also crucial to investigate the splicing factors that control FAK variant generation and develop FAK variant-specific therapeutics. Concurrently, studies should aim to explicit the mechanisms of MHC modulation and explore rational combinations with immunotherapy to address MHC-I heterogeneity. Despite these limitations, the study provides a strong foundation for advancing SCLC therapeutics, particularly through targeting FAK splicing variants.

In conclusion, Wang et al. make substantial contributions to SCLC research through comprehensive multiomics profiling, identifying FAK splicing variants as promising therapeutic targets and revealing complex spatial heterogeneity in the tumor microenvironment. However, the study also highlights significant knowledge gaps in understanding the regulatory mechanisms underlying these phenomena. Addressing these limitations in future research will be crucial for translating these findings into improved clinical outcomes for SCLC patients.

References

[1] Sung H , Ferlay J , Siegel RL , Laversanne M , Soerjomataram I , Jemal A , Bray F . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209–249

[2] Wang GZ , Wang Z , Bai SH , Tan Y , Zhong WZ , Sun GG , Liu YT , Pan B , Huang C , Wang D , Sun BB , Chen DN , Zhang B , Zhou YC , Li S , Zhang XW , Han SC , Yang FY , Shi XY , Jie XL , Shen YK , Liang LJ , Wen ZS , Zhang L , Li MK , Wang N , Liu J , Dong Y , Wang ML , Wang Y , Wang CL , Xie DW , Han ZG , Ying JM , Chen C , Huang YC , Ji HB , Zhang YY , Yu Y , Zhou GB . Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers. Signal Transduct Target Ther 2025; 10(1): 290

[3] George J , Lim JS , Jang SJ , Cun Y , Ozretić L , Kong G , Leenders F , Lu X , Fernández-Cuesta L , Bosco G , Müller C , Dahmen I , Jahchan NS , Park KS , Yang D , Karnezis AN , Vaka D , Torres A , Wang MS , Korbel JO , Menon R , Chun SM , Kim D , Wilkerson M , Hayes N , Engelmann D , Pützer B , Bos M , Michels S , Vlasic I , Seidel D , Pinther B , Schaub P , Becker C , Altmüller J , Yokota J , Kohno T , Iwakawa R , Tsuta K , Noguchi M , Muley T , Hoffmann H , Schnabel PA , Petersen I , Chen Y , Soltermann A , Tischler V , Choi C , Kim YH , Massion PP , Zou Y , Jovanovic D , Kontic M , Wright GM , Russell PA , Solomon B , Koch I , Lindner M , Muscarella LA , la Torre A , Field JK , Jakopovic M , Knezevic J , Castaños-Vélez E , Roz L , Pastorino U , Brustugun OT , Lund-Iversen M , Thunnissen E , Köhler J , Schuler M , Botling J , Sandelin M , Sanchez-Cespedes M , Salvesen HB , Achter V , Lang U , Bogus M , Schneider PM , Zander T , Ansén S , Hallek M , Wolf J , Vingron M , Yatabe Y , Travis WD , Nürnberg P , Reinhardt C , Perner S , Heukamp L , Büttner R , Haas SA , Brambilla E , Peifer M , Sage J , Thomas RK . Comprehensive genomic profiles of small cell lung cancer. Nature 2015; 524(7563): 47–53

[4] Stewart CA , Gay CM , Xi Y , Sivajothi S , Sivakamasundari V , Fujimoto J , Bolisetty M , Hartsfield PM , Balasubramaniyan V , Chalishazar MD , Moran C , Kalhor N , Stewart J , Tran H , Swisher SG , Roth JA , Zhang J , de Groot J , Glisson B , Oliver TG , Heymach JV , Wistuba I , Robson P , Wang J , Byers LA . Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer 2020; 1(4): 423–436

[5] Chan JM , Quintanal-Villalonga Á , Gao VR , Xie Y , Allaj V , Chaudhary O , Masilionis I , Egger J , Chow A , Walle T , Mattar M , Yarlagadda DVK , Wang JL , Uddin F , Offin M , Ciampricotti M , Qeriqi B , Bahr A , de Stanchina E , Bhanot UK , Lai WV , Bott MJ , Jones DR , Ruiz A , Baine MK , Li Y , Rekhtman N , Poirier JT , Nawy T , Sen T , Mazutis L , Hollmann TJ , Pe’er D , Rudin CM . Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell 2021; 39(11): 1479–1496.e18

[6] Rudin CM , Brambilla E , Faivre-Finn C , Sage J . Small-cell lung cancer. Nat Rev Dis Primers 2021; 7(1): 3

[7] Chen Y , Li H , Fan Y . Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy. Cancer Treat Rev 2023; 120: 102606

[8] Kong S , Zhang J , Wang L , Li W , Guo H , Weng Q , He Q , Lou H , Ding L , Yang B . Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy. Cancer Lett 2024; 611: 217432

[9] Fridman WH , Meylan M , Petitprez F , Sun CM , Italiano A , Sautès-Fridman C . B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol 2022; 19(7): 441–457

[10] Romero D . B cells and TLSs facilitate a response to ICI. Nat Rev Clin Oncol 2020; 17(4): 195

[11] Nabet BY , Hamidi H , Lee MC , Banchereau R , Morris S , Adler L , Gayevskiy V , Elhossiny AM , Srivastava MK , Patil NS , Smith KA , Jesudason R , Chan C , Chang PS , Fernandez M , Rost S , McGinnis LM , Koeppen H , Gay CM , Minna JD , Heymach JV , Chan JM , Rudin CM , Byers LA , Liu SV , Reck M , Shames DS . Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell 2024; 42(3): 429–443.e4

[12] Serrels A , Lund T , Serrels B , Byron A , McPherson RC , von Kriegsheim A , Gómez-Cuadrado L , Canel M , Muir M , Ring JE , Maniati E , Sims AH , Pachter JA , Brunton VG , Gilbert N , Anderton SM , Nibbs RJB , Frame MC . Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell 2015; 163(1): 160–173

[13] Lu S , Yu Y , Zhou J , Li X , Goto K , Min X , Nishino K , Cui J , Wu L , Sakakibara J , Shu Y , Dong X , Li L , Yoneshima Y , Zhou C , Li X , Zhang Y , Huang D , Zang A , Zhang W , Wang X , Zhang L , Bai C , Fang J , Cao L , Zhao Y , Yu Y , Shi M , Zhong D , Li F , Duanmu W , Wang Y . Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer. Transl Lung Cancer Res 2025; 14(9): 3924–3938

[14] Paschalis A , Sharp A , Welti JC , Neeb A , Raj GV , Luo J , Plymate SR , de Bono JS . Alternative splicing in prostate cancer. Nat Rev Clin Oncol 2018; 15(11): 663–675

[15] Papavassiliou KA , Sofianidi AA , Gogou VA , Anagnostopoulos N , Papavassiliou AG . P53 and RB aberrations in small cell lung cancer (SCLC): from molecular mechanisms to therapeutic modulation. Int J Mol Sci 2024; 25(5): 2479

[16] Zhou G . Tobacco, air pollution, environmental carcinogenesis, and thoughts on conquering strategies of lung cancer. Cancer Biol Med 2019; 16(4): 700–713

RIGHTS & PERMISSIONS

Higher Education Press